News & Updates

In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.

Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.

Treatment with sotrovimab reduces the risk of all-cause hospitalization or death in patients with COVID-19 who are at high risk of progression to severe disease, regardless of anti-SARS-CoV-2 serostatus, according to a study presented at CROI 2022.

Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.

Most patients with inflammatory bowel disease (IBD) build an initial immune response to SARS-CoV-2 vaccination, but older patients, those treated with antitumour necrosis factor (anti-TNF) and an immunomodulator, and those on corticosteroids may require an additional vaccine dose to achieve better immunity against COVID-19, according to a study.

Use of oral antibiotics in the treatment of osteomyelitis, bacteraemia, and infective endocarditis results in shorter hospital stay, has a better safety profile, and appears to be similarly effective when compared to intravenous (IV)-only therapy, a recent study has shown.

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.